Summit’s PD-1xVEGF rejected by FDA in lung cancer
Ivonescimab, the PD-1xVEGF bispecific antibody brought over to the U.S. from China by Summit Therapeutics, has been denied approval by…
Ivonescimab, the PD-1xVEGF bispecific antibody brought over to the U.S. from China by Summit Therapeutics, has been denied approval by…